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mortality attributed to the use of central venous
catheters: a retrospective cohort study
Karthik K Tennankore1*, Steven D Soroka2 and Bryce A Kiberd2Abstract
Background: Central venous catheters (CVCs) are associated with early mortality in dialysis patients. However, some
patients progress to end stage renal disease after an acute illness, prior to reaching an estimated glomerular
filtration rate (eGFR) at which one would expect to establish alternative access (fistula/peritoneal dialysis catheter).
The purpose of this study was to determine if exclusion of this “acute start” patient group alters the association
between CVCs and mortality.
Methods: We conducted a retrospective cohort study of 406 incident dialysis patients from 1 Jan 2006 to 31 Dec
2009. Patients were classified as acute starts if 1) the eGFR was >25 ml/min/1.73 m2, ≤3 months prior to dialysis
initiation and declined after an acute event (n = 45), or 2) in those without prior eGFR measurements, there was no
supporting evidence of chronic kidney disease on history or imaging (n = 12). Remaining patients were classified as
chronic start (n = 349).
Results: 98 % and 52 % of acute and chronic starts initiated dialysis with a CVC. There were 148 deaths. The
adjusted mortality hazard ratio (HR) for acute vs. chronic start patients was 1.84, (95 % CI [1.19-2.85]). The adjusted
mortality HR for patients dialyzing with a CVC compared to alternative access was 1.19 (95 % CI [0.80-1.77]). After
excluding acute start patients, the adjusted HR fell to 1.03 (95 % CI [0.67-1.57]).
Conclusions: A significant proportion of early dialysis mortality occurs after an acute start. Exclusion of this
population attenuates the mortality risk associated with CVCs.
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Incident use of central venous catheters (CVCs) as initial
hemodialysis (HD) access is associated with increased
mortality in prospective studies and large registry ana-
lyses [1-4]. While CVCs are more common in late refer-
rals [5], they are associated with a higher mortality risk
compared to arteriovenous fistulas (AVFs) even after
adjusting for timing of referral [1]. Dialysis with a CVC is
also associated with a higher risk of death compared to
peritoneal dialysis (PD) [6]. As a result of the association
between CVCs and mortality in HD, guidelines recom-
mend the use of an AVF as initial HD access [7-9].* Correspondence: ktennankore@gmail.com
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distribution, and reproduction in any mediumRecognizing that AVFs require time to mature, guidelines
also suggests that AVF creation should occur in a timely
fashion. Timely initiation of PD in patients with chronic
kidney disease (CKD) is also emphasized [10]. Despite
these recommendations, most incident patients continue
to dialyze with a CVC [2,6].
With a few exceptions [11,12], CVCs are used as initial
dialysis access in patients with acute renal failure/acute
kidney injury (AKI) or acute on early stage chronic kid-
ney disease (ACKD), as timely placement of alternative
access is not a consideration in these patients. As high
as 16 % and 28 % of patients do not recover kidney func-
tion after acute renal failure [13] and ACKD [14], re-
spectively. In addition, progression to end stage renal
disease (ESRD) in both these situations is itself asso-
ciated with increased mortality [13,14].ntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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dialysis start” confounded the association between CVCs
and mortality [15]. However, this study did not separ-
ately analyze patients with an acute decline in GFR from
patients presenting emergently with late stage CKD. A
recent case series identified that a rapid decline in esti-
mated glomerular filtration rate (eGFR; in patients with
an eGFR >30 ml/min/1.73 m2) may be an unavoidable
cause of incident use of CVCs, but did not examine its
association with mortality [16].
Therefore, in a retrospective cohort of incident dialysis
patients, the purposes of this study were to explore the
following:
1) Determine the proportion of incident dialysis
patients who develop ESRD after a permanent loss of
GFR in the context of an acute illness event (“acute
start”).
2) Identify if patients who start dialysis under this
circumstance are at an increased risk of mortality.
3) Determine if CVCs are associated with mortality,
and if this association persists after excluding
patients with an illness induced permanent GFR loss.
We hypothesize that CVC mortality may be overesti-
mated without considering the influence of an acute start.
Methods
Population
We conducted a retrospective cohort study consisting of
481 consecutive, adult (> 18 years) ESRD dialysis starts at
a tertiary care center in Halifax, Nova Scotia, Canada
over a period of 48 months (1 Jan 2006 to 31 Dec 2009).
We chose this time frame to coincide with the availability
of electronic patient/ESRD database records at our insti-
tution (which commenced just prior to Jan 2006), and
ensure a minimum of one year of follow-up from the last
date of study entry. Patients were excluded if they trans-
ferred to another regional dialysis unit (Prince Edward
Island, Cape Breton or Yarmouth) or out of province
after having received only their initial HD in Halifax.
Exposure assessment
Patients were classified as “acute start” under the follow-
ing circumstances:
1) eGFR by MDRD >25 ml/min/1.73 m2 ≤ three months
prior to dialysis initiation that declined in the
context of an acute illness event requiring
hospitalization.
2) Acute illness event leading to dialysis initiation in
patients without prior eGFR measurements and no
suggestion of chronic kidney disease on history or
renal ultrasound [16].Remaining patients were classified as “chronic start”:
1) eGFR by MDRD ≤25 ml/min/1.73 m2 > three months
prior to dialysis initiation.
2) eGFR by MDRD >25 ml/min/1.73 m2 ≤ three months
prior to dialysis initiation without a documented
acute illness event.
3) Late presentation of ESRD, suggested by ultrasound
evidence of bilateral small kidneys in individuals
without prior eGFR measurements [17].
The definition of an acute start was made on the as-
sumption that most patients are not referred for evalu-
ation and/or placement of AVF or PD catheter access
prior to reaching an eGFR of <25 ml/min/1.73 m2. This
is consistent with previously published guideline recom-
mendations on appropriate referral for permanent access
placement [7,9]. Therefore, we expected that the vast
majority of patients with an eGFR of >25 ml/min/
1.73 m2 who progressed to ESRD within three months
would be unexpected dialysis starts without established
or planned alternative access.
Access at dialysis initiation was classified as a central
venous catheter (CVC), peritoneal dialysis (PD) catheter
or arteriovenous fistula (AVF). There was only one ar-
teriovenous graft at this center and for the purpose of
this study it was classified as a fistula. AVF access
required completion of one dialysis treatment with the
AVF. PD access required successful completion of the
training program. No incident patients were on combin-
ation therapy. All patient definitions were independently
assessed by a nephrologist and nephrology fellow, subse-
quent to which consensus was achieved.
Baseline data
Clinical data, including cause and date of death was
accessed from individual patient Canadian Organ Re-
placement Registry (CORR) forms and supplemented
with electronic patient record data. In addition to cause
of ESRD, date of dialysis initiation and access type, a
Charlson Comorbidity Index (CCI) was calculated at the
time of dialysis start in all incident patients. This index
allocates different point scores to 19 individual medical
conditions depending on the risk of mortality associated
with each condition [18]. We also collected several la-
boratory parameters including creatinine, phosphate,
hemoglobin and albumin in all patients at baseline. All
assays were performed by the institution’s laboratory.
We manually calculated a four variable modified diet in
renal disease (MDRD) eGFR at dialysis initiation in all
patients, using available creatinine measurements. In
addition, we used electronic chart and laboratory sys-
tems review to identify available outpatient creatinine
values (from which we calculated eGFRs) at 1, 3, 6, 9
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a ± two-week time frame at each time interval. Finally,
the acute event prompting dialysis initiation in acute
start patients was determined using electronic patient
records.
Outcome
We initially examined the time to all cause mortality
from dialysis initiation for acute vs. chronic start
patients and for CVC vs. PD/AVF access. After exclud-
ing acute start patients, the primary outcome of this
study was to analyze the time to death for CVC vs. PD/
AVF access. Patient survival was censored at transplant-
ation or date of last follow-up (31 Mar 2011).
Statistical analysis
Results were reported as counts and percentages for cat-
egorical variables, mean ± standard deviation for nor-
mally distributed continuous variables and median and
interquartile range for non-normally distributed con-
tinuous variables. Categorical variables were compared
using the Fisher’s Exact Test. Continuous variables were
compared with t-tests and the Wilcoxon Rank Sum Test
for normally and non-normally distributed variables, re-
spectively. In addition, we performed an analysis of base-
line characteristics restricted to chronic start patients,
using the same statistical methods outlined above. Miss-
ing laboratory data was addressed using regression mean
imputation. Complete variables chosen to impute miss-
ing data were age, gender, CCI and referral days. The
time to mortality was graphed using the Kaplan-Meier
product limit method and adjusted Cox survival curves.
Adjusted hazard ratios and 95 % confidence intervals
(CI) were estimated from multivariable Cox proportionalFigure 1 Cohort selection.hazards models. Variables selected for inclusion in the
models were based on clinical judgment and known pre-
dictors derived from the literature. These variables
included age, CCI, ESRD due to diabetes, gender, refer-
ral time, albumin, hemoglobin, phosphate and eGFR
[19-26]. Interactions were examined for all variables
used in the Cox survival analysis. Proportionality was
examined with the test based on scaled Schoenfeld resi-
duals. In addition to the primary analysis, we performed
sensitivity analyses without censoring at transplantation,
and using an eGFR cut-off of 30 ml/min/1.73 m2. All
statistical analyses were performed using STATA IC,
version 12 (StataCorp, College Station, TX). A two-
sided P value < 0.05 was considered statistically signifi-
cant. This study was approved by the Queen Elizabeth
II Health Sciences Centre research ethics board, our in-
stitutional research ethics committee.
Results
All patients
After exclusions (Figure 1), 406 patients were followed
for a median of 22 months (IQR 13 to 35 months). 57
and 349 patients met the criteria for acute and chronic
start, respectively. Amongst the chronic start patients,
335 fulfilled the definition based on eGFR criteria. One
patient had an eGFR > 25 ml/min/1.73 m2 within three
months of dialysis initiation, but without an acute illness
event. The remaining 14 chronic start patients did not
have eGFRs available between 12 and 3 months prior to
starting dialysis, but small kidneys on ultrasound sug-
gesting preexisting chronic kidney disease. Baseline char-
acteristics of both groups are noted in Table 1. 36/57
and 9/57 acute start patients (63 % and 16 %) had eGFR
measurements available at three and one month prior to







Age at dialysis start, years,
(mean± SD)
71 ± 12.0 62 ± 16 <0.001
Male gender, n (%) 32 (57) 202 (58) 0.89
Caucasian race, n (%) 50 (88) 323 (93) 0.20
Dialysis Access, n (%)
CVC 56 (98) 182 (52) <0.001
AVF 1 (2) 95 (27) <0.001
PD catheter 0 72 (21) <0.001
Cause of ESRD, n (%)
Diabetes 8 (14) 110 (32) 0.007
Polycystic kidney disease 2 (4) 30 (9) 0.29




3, 1 to 33 1087,
443 to 2571
<0.001
Referral < 3 months, n (%) 47 (82) 34 (10) <0.001
Comorbidity
CCI (median, IQR) 5, 3 to 7 4, 2 to 6 0.03
Diabetes, n (%) 23 (41) 154 (44) 0.38
Coronary artery disease, n (%) 15 (27) 100 (29) 0.73
Congestive heart failure, n (%) 17 (30) 77 (22) 0.18
Peripheral vascular disease n (%) 14 (25) 78 (22) 0.73
Malignancya, n (%) 17 (30) 34 (10) <0.001
Laboratory Values
Hemoglobin, g/L, (mean± SD) 93 ± 15 100 ± 17 0.004
Albumin, g/L, (median, IQR) 26, 23 to 30 33, 28 to 36 <0.001
Phosphate, mmol/L,
(median, IQR)
1.9, 1.4 to 2.6 1.8, 1.5 to 2.2 0.33
Imputed phosphateb 1.9, 1.5 to 2.6 1.9, 1.5 to 2.6 0.26
eGFR, ml/min/1.73 m2,
(median, IQR)
6.8, 5.0 to 9.0 7.8, 6.0 to 10 0.01
Imputed eGFRc 6.8, 5.0 to 9.0 7.8, 6.0 to 10 0.01
a: Including hematologic or non-hematologic, excluding non-melanoma skin
cancer.
b: 31 missing values imputed.
c: 3 missing values imputed.
Tennankore et al. BMC Nephrology 2012, 13:72 Page 4 of 9
http://www.biomedcentral.com/1471-2369/13/72dialysis initiation. The mean eGFR of these groups was
44 and 50 ml/min/1.73 m2, respectively. Of the
remaining 12 patients without prior eGFR measure-
ments, 8 had rapidly progressive glomerulonephritis
(RPGN), 3 had multiple myeloma and 1 had pneumonia.
The acute events leading to dialysis initiation in all acute
start patients are noted in Figure 2.
At last follow up, there were 62 kidney transplants and
148 deaths. 4/38 acute and 2/110 chronic start deaths
were attributed to catheter-related sepsis (11 % and 2 %
respectively). Causes of death are noted in Table 2. Thetwo chronic start patients that died of catheter-related
sepsis were 68 and 86 years of age. The first had a failed
attempt at fistula creation prior to dialysis, and the latter
chose PD but had an absolute contraindication due to a
lack of home support and dementia. One additional
chronic start patient (86 years of age), died from compli-
cations related to the CVC (superior vena cava throm-
bosis). This patient refused fistula creation prior to
dialysis initiation. In the fully adjusted Cox model, an
acute dialysis start was associated with shorter time to
mortality compared to a chronic start (HR 1.84, 95 % CI
[1.19-2.85], Table 3). Kaplan Meier survival curves for
acute and chronic start patients are noted in Figure 3.
CVC associated mortality
In the fully adjusted Cox model, the mortality HR for
CVC vs. PD/AVF access was 1.19 (95 % CI, [0.80-1.77]).
After excluding all acute starts, 349 chronic start
patients remained for further analysis. Of these patients,
182 (52 %) initiated dialysis with a CVC. Baseline char-
acteristics of patients dialyzing with a CVC vs. alterna-
tive access (PD catheter or AVF) are noted in Table 4. In
the fully adjusted Cox model for chronic dialysis start
patients, the mortality HR for CVCs vs. PD/AVF access
was 1.03 (95 % CI [0.67 to 1.57], Table 5). Adjusted Cox
survival curves for CVC vs. PD catheter/AVF access in
the complete and restricted cohort are noted in Figure 4.
Discussion
In this single center study of consecutive incident dialy-
sis patients, we identified that a proportion of patients
with a normal eGFR or early stage CKD (1 to early stage
4), initiated dialysis after an illness that induced a per-
manent, rapid loss of eGFR. Virtually all of these
patients used a CVC as initial dialysis access. While this
acute start patient group made up only a small percent-
age of all dialysis starts, they were at an increased risk
for mortality compared to chronic start patients. Finally,
CVCs were associated with a trend to increased mortal-
ity, but amongst chronic dialysis starts, the mortality risk
of CVCs was attenuated and comparable to patients
with alternative access.
For the chronic start patients, there are potential rea-
sons that dialysis access was not associated with
increased mortality, a finding in contrast to large registry
studies [2,6]. An association between mortality and AKI/
ACKD leading to ESRD has been demonstrated in previ-
ous studies [13,14,27]. The majority of these patients ini-
tiate dialysis with a CVC. However, even patients with
non-dialysis requiring AKI have a higher mortality risk
compared to those without AKI [28]. This emphasizes
that the association between CVC access and mortality
(in AKI patients who do not recover kidney function)
may be the result of AKI itself. Alternatively AKI or
Figure 2 Acute illness event leading to dialysis initiation. Causes for category “other” were as follows: toxic acute tubular necrosis (ATN),
atheroemboli, hypovolemic ischemic ATN, scleroderma renal crisis, tumour lysis syndrome (1 for each).
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been known to influence mortality in dialysis patients,
such as residual renal function [29,30]. If these patients
are not excluded from studies of incident dialysis and
mortality, the mortality risk of CVCs may be overesti-
mated. Another consideration is that the comparable
survival for CVC vs. AVF/PD catheter access after exclu-
sion of acute starts may be related to access conversion.






Catheter-related sepsis 4 2
Sepsis: other source 7 10
Cardiac (valvular, arrest, congestive
heart failure, acute coronary syndrome)
7 30
Neurologic (stroke, seizure, delirium,
demyelinating, dementia)
6 11
Non myeloma cancer 9
Multiple myeloma 3 1








b: Cirrhosis, failed bone marrow transplant, suicide, calciphylaxis, refractory
hypotension, superior vena cava thrombosis.shown that conversion from a CVC to an AVF after dia-
lysis initiation is associated with increased survival [31].
The suggestion that the CVC associated mortality may
be overestimated is further supported in our analysis of
cause of death. Only 7/148 patient deaths (5 %) were
clearly a direct result of the CVC itself (infection or vas-
cular thrombosis). 4 of the 7 patient deaths were acute
starts, a population who may be at an increased risk of
hospital acquired bacteremia from other sources. While
cause of death may have been subject to classification
error, we were able to corroborate data with electronic
records in this study. In contrast, registry studies may
not always have access to individual records to confirm
or refute cause of death [32].
However, even if CVC related mortality was underesti-
mated in this study, complete avoidance of CVCs may
be unrealistic and unachievable for a large number of in-
cident dialysis patients. The three chronic start patients
who died of catheter sepsis had largely unavoidable rea-
sons for CVC use including previous access failure and
patient refusal of alternative access. Furthermore, a re-
cent study determined that the majority of late referred
ESRD dialysis starts are unavoidable [33], and it can be
assumed that many of these patients start dialysis with a
CVC. This assumption was confirmed in our study,
namely, that a sizeable proportion of patients develop
ESRD after a rapid loss of eGFR, a setting in which alter-
native access is not anticipated. The notion that CVCs
should be avoided at all costs also needs to be reconsid-
ered in light of AVF success rates. Fistulas continue to
have a high primary non-function rate [34-36]. The util-
ity of AVFs is also questioned in many older patients.
Table 3 Cox survival analysis for acute vs. chronic start
patients
Model HR [95 % CI] P
Unadjusted 2.83 [1.95 to 4.09] <0.001
Model 1a 2.56 [1.76 to 3.71] <0.001
Model 2b 2.35 [1.59 to 3.47] <0.001
Model 3c 2.14 [1.42 to 3.22] <0.001
Model 4d 1.84 [1.19 to 2.85] 0.006
a: Adjusted for age and gender.
b: Adjusted for factors in a. CCI and ESRD due to diabetes.
c: Adjusted for factors in b. and referral days.
d: Adjusted for factors in c. hemoglobin, albumin, phosphate and eGFR.
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prior to dialysis access and the significant early mortality
risk of elderly CKD patients with functioning access
after the start of dialysis [37,38]. Overall, these scenarios
suggest that while AVF and PD catheter access are pre-
ferred, there will still be considerable numbers of dialysis
starts that will not be optimal despite our best efforts
[39,40].
The findings of our study need to be compared to
other cohort studies examining the association between
dialysis access, acute start and mortality. The findings in
our study were similar to a recent analysis of Veterans
Affairs (VA) patients in which a “catastrophic loss of
eGFR” (defined as loss from levels >60 ml/min/1.73 m2
within 6 months or less) was associated with early mor-
tality [41]. While those patients initiated dialysis at a
higher eGFR than our study (in part because the defin-
ition of predialysis eGFR was different), both studies
highlight the importance of a rapid eGFR decline and its
impact on mortality. In a large French REIN registryFigure 3 Kaplan Meier survival curves for acute and chronic start patanalysis of incident dialysis patients with congestive
heart failure (CHF), despite excluding unplanned dialysis
starts, CVC use was still associated with a statistically
significant mortality HR of 1.35 (95 % CI 1.22-1.49) [42].
However, unlike the REIN study, our cohort had both
CHF and non-CHF patients. In addition, the definition
of an acute start differs from the unplanned definition
used in REIN cohort studies [42,43]. We only classified
AKI/ACKD patients who started dialysis as “acute
starts”, but not those with previously undiagnosed or un-
investigated late stage CKD who presented late. While
speculative, the latter may be a group of “survivors” (by
virtue of being able to survive to the point of getting dia-
lysis access) that would have been excluded from the
REIN chronic cohort of planned dialysis starts.
There are limitations to this study. Three-month eGFR
measurements were not available in all patients and
ultrasound or patient history may be inaccurate in differ-
entiating acute and chronic kidney disease. However,
using the criteria in our definition, and considering the
acute events in this patient group (primarily RPGN and
myeloma) it was not illogical to classify patients as an
acute start when eGFRs were not readily available. While
the accuracy of our ESRD database is enhanced by its
use of detailed electronic records, we acknowledge that
there may have been some patients with AKI and early
mortality that were misclassified as ESRD patients, or
ESRD acute starts that were not included in this study.
Because of a lack of frequent eGFR measurements in all
patients, it was not possible to accurately capture the
rate of eGFR decline and incorporate it into the defin-
ition. Some authorities may advocate for placement of a
fistula or PD catheter at an eGFR >25 ml/min/1.73 m2 ifients.
Table 4 Baseline characteristics of chronic start dialysis







Age at dialysis start, years,
(mean± SD)
62 ± 16.0 62 ± 16 0.95
Male gender, n (%) 96 (53) 106 (63) 0.05
Caucasian race, n (%) 166 (91) 157 (94) 0.42
Dialysis Access, n (%)
CVC 56 (98) 182 (52) <0.001
AVF 1 (2) 95 (27) <0.001
PD catheter 0 72 (21) <0.001
Cause of ESRD, n (%)
Diabetes 64 (35) 46 (28) 0.14
Polycystic kidney disease 9 (5) 21 (13) 0.01
Glomerulonephritis 23 (13) 22 (13) 1.00
Referral time before dialysis






Referral < 3 months, n (%) 32 (18) 2 (1) <0.001
Comorbidity
CCI (median, IQR) 5, 3 to 7 3, 2 to 6 <0.001
Diabetes, n (%) 91 (50) 63 (38) 0.02
Coronary artery disease, n (%) 62 (34) 38 (23) 0.02
Congestive heart failure, n (%) 44 (24) 33 (20) 0.37
Peripheral vascular disease n (%) 54 (30) 24 (14) 0.001
Malignancya, n (%) 23 (13) 11 (7) 0.07
Laboratory Values
Hemoglobin, g/L, (mean± SD) 96 ± 17 105 ± 17 <0.001
Albumin, g/L, (median, IQR) 31, 25 to 34 34, 31 to 38 <0.001
Phosphate, mmol/L,
(median, IQR)
1.8, 1.5 to 2.3 1.8, 1.5 to 2.2 0.19
Imputed phosphateb 1.9, 1.6 to 2.3 1.8, 1.5 to 2.1 0.13
eGFR, ml/min/1.73 m2,
(median, IQR)
7.2, 5.8 to 9.7 8.1, 6.2 to 10.9 0.01
Imputed eGFRc 7.3, 5.8 to 9.6 8.1, 6.2 to 10.9 0.01
a: Including hematologic or non-hematologic, excluding non-melanoma skin
CA.
b: 21 missing values imputed.
c: 3 missing values imputed.
Table 5 Cox survival analysis for CVC vs. AVF/PD catheter
access
Model HR [95 % CI] P
Complete cohort (n = 406)
Unadjusted 1.70 [1.20 to 2.41] 0.003
Model 1a 1.73 [1.22 to 2.45] 0.002
Model 2b 1.55 [1.08 to 2.22] 0.02
Model 3c 1.41 [0.97 to 2.05] 0.07
Model 4d 1.19 [0.80 to 1.77] 0.40
Model 4d without censoring at transplantation 1.16 [0.78 to 1.73] 0.45
Excluding acute start patients (n = 349)
Unadjusted 1.36 [0.93 to 2.00] 0.11
Model 1a 1.42 [0.97 to 2.09] 0.07
Model 2b 1.28 [0.87 to 1.90] 0.21
Model 3c 1.23 [0.83 to 1.84] 0.30
Model 4d 1.03 [0.67 to 1.57] 0.91
Model 4d without censoring at transplantation 0.99 [0.64 to 1.51] 0.95
Excluding acute start patients with an eGFR>30 ml/min/1.73 m2
(n = 359)
Unadjusted 1.42 [0.97 to 2.06] 0.07
Model 1a 1.46 [1.00 to 2.13] 0.05
Model 2b 1.32 [0.89 to 1.94] 0.16
Model 3c 1.26 [0.85 to 1.87] 0.24
Model 4d 1.05 [0.69 to 1.61] 0.81
Model 4d without censoring at transplantation 1.02 [0.67 to 1.55] 0.94
a: Adjusted for age and gender.
b: Adjusted for factors in a. CCI and ESRD due to diabetes.
c: Adjusted for factors in b. and referral days.
d: Adjusted for factors in c. hemoglobin, albumin, phosphate and eGFR.
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However, a sensitivity analysis using a more conservative
eGFR cutoff of >30 ml/min/1.73 m2 (corresponding to
the lower limit of stage 3 CKD), did not change the
results of our study. A final limitation of our definition
of acute start is that fistulas or PD catheters can be
placed and accessed within 3 months of identifying a
need for dialysis. However, our population also required
an acute illness event to precipitate the decline in eGFR
prior to dialysis initiation. Therefore, most physicianswould be unprepared to institute optimal access place-
ment in this population. This would be true for patients
with a recent cardiac/septic event or admission in an in-
dividual with potentially reversible AKI (i.e. myeloma or
RPGN). In addition to the study population, there are
other limitations inherent to the study design. Despite
controlling for multiple variables, there is the possibility
of residual confounding and bias. It is possible that a lar-
ger study may detect a small, persistent, residual early
mortality risk associated with CVCs. Furthermore, while
we attempted to capture all of the CVC related deaths,
15 % of deaths amongst chronic start patients were of
unknown cause. It is possible that additional catheter-
related septic deaths were missed in this group.
It should be emphasized that while this study suggests
that the mortality attributed to CVCs needs to be exam-
ined after consideration of an “acute start”, we are not
suggesting that CVCs are optimal dialysis access. We ac-
knowledge that our patients may have developed CVC
complications that indirectly led to alternative causes of
death or morbidity. Moreover, given CVCs are associated
Figure 4 Adjusted Cox survival curves for CVC vs. PD catheter/AVF access in A) all patients and B) chronic start patients.
Tennankore et al. BMC Nephrology 2012, 13:72 Page 8 of 9
http://www.biomedcentral.com/1471-2369/13/72with significant morbidity and cost [44-47], there should
be concerted efforts to obtain alternative access in preva-
lent dialysis patients.Conclusion
In summary, an acute dialysis start is associated with
increased mortality and exclusion of this population
attenuates the mortality risk of CVC use. Prior registry
reports may have overestimated CVC mortality, as acute
starts were not considered. Additional studies should be
conducted to further establish the potential modifying
effect of an acute start on CVC associated mortality.
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